Wednesday, February 5, 2020
Professor of Law and Faculty Director of the Global Health Justice Partnership Amy Kapczynski ’03 is quoted in a CNBC story about quarantines for patients suspected of having the coronavirus.
Thursday, October 10, 2019
On October 3, 2019, panelists at Yale Law School discussed the implications of gendered and racialized sports eligibility requirements on athletes’ bodily autonomy and rights.
Wednesday, May 15, 2019
Gilead Sciences used its monopoly on one critical component in HIV combo meds to stifle generic competition and keep prices high, a new lawsuit claims—and the Big Biotech did so with the help of combo partners Johnson & Johnson and Bristol-Myers Squibb.
Tuesday, May 14, 2019
Gilead forged deals that blocked generic competition, even after Gilead’s brand patents on key medications in the combination pills expired, according to the civil antitrust lawsuit brought in U.S. District Court in San Francisco by HIV/AIDS activists and two service unions.
Monday, May 13, 2019
A new report from the Yale Global Health Justice Partnership (GHJP) at the Yale Law School and the Yale School of Public Health finds that Increasing rates of drug-related incarcerations are perpetuating tuberculosis (TB) infection among Brazil’s general population.
Friday, March 29, 2019
On March 20, 2019 the Solomon Center for Health Law and Policy at Yale Law School hosted a discussion on U.S. Representative Rosa DeLauro’s proposed Medicare for America (MFA) plan.
Wednesday, March 27, 2019
The Yale Global Health Justice Partnership (GHJP) joined the PrEP4All Collaboration (PrEP4All) in calling on the Centers for Disease Control and Prevention (CDC) to use its patents on HIV pre-exposure prophylaxis (PrEP) to promote universal access to PrEP within the United States.
Tuesday, March 26, 2019
An HIV treatment cost taxpayers millions. The government patented it. But a pharma giant is making billions.
Christopher J. Morten, a fellow at the Global Health Justice Partnership, is quoted in an article about a drug manufacturer profiting from an HIV prevention treatment paid for and patented by the government.